Charlie Rowland

Charlie Rowland is an accomplished professional with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as a Board Member and Audit Committee Chair at Generation Bio since August 2018, Rowland has held multiple board roles, including positions at Viking Therapeutics, Nabriva Therapeutics, Orchard Therapeutics, and Blueprint Medicines, showcasing expertise in compensation and audit committees. Previous experience includes leadership as President & CEO of Aurinia Pharmaceuticals and significant board positions at companies such as Vitae Pharmaceuticals and BIND Therapeutics. Rowland possesses an MBA in Finance from Rutgers University - Newark and a BS in Accounting from Saint Joseph's University.